<DOC>
	<DOCNO>NCT00816166</DOCNO>
	<brief_summary>The main objective study prospectively evaluate safety , probable benefit , effectiveness PHAROS Vitesse Neurovascular Stent System multicenter , randomize clinical trial . A secondary objective study evaluate impact stenting neurovasculature treat cerebral ischemia outcome hospital length stay , charge , cost .</brief_summary>
	<brief_title>VISSIT Intracranial Stent Study Ischemic Therapy</brief_title>
	<detailed_description>1.1 Study Hypothesis Treatment cerebral retinal ischemia due plaque neurovasculature use PHAROS Vitesse Stent System plus medical therapy provide additional clinical benefit medical therapy alone . 1.2 Primary Effectiveness Endpoint The primary effectiveness endpoint consist composite two follow outcome : - Stroke territory ( distal target lesion ) present event within 12 month randomization - Hard TIA territory ( distal target lesion ) present event day 2 month 12 post-randomization 1.3 Safety Outcomes Safety outcomes collect reported part overall risk-to-benefit profile device : - Stroke territory within 30 day randomization - Death cause within 30 day randomization - Hard TIA territory occur 24 hour post-procedure stabilization period ( day 2-30 ) since recovery anesthesia mask accurate assessment possible TIA symptom . - Intracranial hemorrhage within 30 day randomization 1.4 Other Outcomes - Stent Success - PHAROS Vitesse stent deploy across target lesion residual stenosis 0-20 % - Percentage Stent Group Subjects ( symptomatic asymptomatic ) in-stent restenosis ≥ 70 % confirm angiogram 12 month - Percentage Stent Group Subjects symptomatic in-stent restenosis ≥ 70 % confirm angiogram 12 month - Percentage Medical Therapy Group Subjects interventional procedure ( e.g. , angioplasty stent ) 12 month - Comparison NIHSS score treatment arm - Comparison mRS score treatment arm</detailed_description>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Ischemic Attack , Transient</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<criteria>1 . Subject least one neurovascular lesion ( 7099 % ) stenosis [ internal carotid , middle cerebral , vertebral artery ( C4BA ) , and/or basilar artery ] symptomatic hard TIA stroke attributable territory lesion within past 30 day . An intracranial tandem lesion ( 5099 % ) stenosis may treat normal artery segment sufficient length avoid overlap stent . 2 . Target vessel diameter / lesion length measurement within one per angiogram : Vessel diameter ≥ 2.0 mm &lt; 2.5 mm / lesion length ≤ 16 mm , Vessel diameter ≥ 2.5 mm &lt; 3.0 mm / lesion length ≤ 18 mm , Vessel diameter ≥ 3.0 mm &lt; 4.5 mm / lesion length ≤ 26 mm , Vessel diameter ≥ 4.5 mm ≤ 5.0 mm / lesion length ≤ 31 mm 3 . Subject normal artery adjacent stenosis ; diameter 2.0 mm 5.0 mm 4 . Subject age 1885 year 5 . Life expectancy least 2 year 6 . Subject 's mRS score ≤ 3 7 . Subject available study followup visit ( e.g. , live within 3 hour research center ) 8 . Subject willing cognitively able provide Informed Consent ( consent may indicate verbally sign neutral witness stroke impaired hand visual function ) 1 . Subject contraindication balloon expandable stent , e.g . Extreme tortuosity , proximal , target lesion , More 2 lesion &gt; 50 % stenosis ( include vertebral ostia common carotid disease ) , Carotid vertebral dissection 2 . CT scan MRI evidence follow : Intracranial hemorrhage type PH1 PH2 Subdural epidural hemorrhage Mass effect , Intracranial tumor ( except small meningioma ) 3 . Subject previous stent territory target lesion ( ) 4 . Subject previous coil clip place territory target lesion within 6 month 5 . Subject potential source cardiac embolism require anticoagulation therapy ( e.g. , atrial fibrillation , intracardiac thrombus vegetation , significant mitral stenosis , mechanical heart valve , congestive heart failure EF &lt; 30 % , endocarditis ) 6 . Subject concurrent intracranial pathology , e.g . Moyamoya Vasculitis document biopsy result Ruptured Aneurysm Unruptured aneurysm &gt; 7mm 7 . Subject uncontrolled hypertension ( systolic &gt; 185 mmHg diastolic &gt; 110 mmHg ) 8 . Hemoglobin &lt; 10 g/dL ; platelet count &lt; 100,000 ; INR &gt; 1.5 ( e.g. , use warfarin ) 9 . Subject uncorrectable bleeding diathesis 10 . Subject 's neurological status unstable rapidly decline ( NIHSS score increase &gt; 4 point within 48 hour prior randomization ) 11 . Subject contraindication combination antithrombotic treatment ( e.g. , clopidogrel aspirin ) peptic ulcer disease 12 . Subject history indicate high risk noncompliance ( e.g. , substance abuse , psychosocial issue , etc . ) 13 . Subject known history contraindicate contrast dye iodine ( vs. sensitivity safely control antihistamine , steroid , etc . ) 14 . Subject pregnant plan become pregnant next 12 month 15 . Myocardial infarction within past 3 month 16 . Treatment tPA thrombolytic agent within 48 hour prior randomization 17 . Major surgery trauma within 2 week prior randomization 18 . Enrollment another investigational device drug study may confound result</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Ischemic stroke</keyword>
	<keyword>Transient Ischemic Attack</keyword>
	<keyword>Intracranial Stenting</keyword>
</DOC>